Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into valuable clinical tools. The Company’s flagship product, the Eeva™ Test, is designed to deliver consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions.
Funding Rounds (4) - $44MUpdate
Board Members and Advisors (3)Update
1490 O’Brien Drive
Menlo Park, CA 94025